Samalin Investment Counsel LLC Purchases Shares of 84,575 Nkarta, Inc. (NASDAQ:NKTX)

Samalin Investment Counsel LLC purchased a new stake in Nkarta, Inc. (NASDAQ:NKTX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 84,575 shares of the company’s stock, valued at approximately $211,000. Samalin Investment Counsel LLC owned 0.12% of Nkarta at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sei Investments Co. acquired a new position in shares of Nkarta in the 4th quarter valued at about $57,000. American Century Companies Inc. lifted its position in Nkarta by 8.8% during the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company’s stock worth $226,000 after acquiring an additional 7,378 shares in the last quarter. Thrivent Financial for Lutherans acquired a new position in Nkarta during the 4th quarter worth approximately $258,000. Sequoia Financial Advisors LLC acquired a new position in Nkarta during the 4th quarter worth approximately $31,000. Finally, Catalina Capital Group LLC lifted its position in Nkarta by 57.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock worth $47,000 after acquiring an additional 6,867 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Insider Buying and Selling at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. This represents a 5.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 8.70% of the stock is currently owned by corporate insiders.

Nkarta Price Performance

Shares of NKTX opened at $1.50 on Monday. The business’s 50 day moving average is $2.06 and its two-hundred day moving average is $2.96. Nkarta, Inc. has a 52-week low of $1.44 and a 52-week high of $11.84. The firm has a market cap of $105.85 million, a price-to-earnings ratio of -0.80 and a beta of 0.90.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.